Psoriasis

The company announced the results from its long-term extension study, highlighting improved efficacy outcomes, quality of life, and tolerability data.

In a recent study from the Journal of the American Academy of Dermatology, investigators assessed symptoms, disease burden, and use of analgesics in patients with or without psoriatic arthritis.

A recent study examined the role of inflammation and psoriasis in cardiometabolic diseases, focusing on metabolic syndrome and its components.

The calcipotriene and betamethasone dipropionate cream is for the treatment of mild to moderate plaque psoriasis in adult patients, including the scalp.

An article the in Journal of the American Academy of Dermatology examined the possible connection between psoriasis and colorectal cancer.

A recent study examined the link between psoriasis clearance, quality of life, and an uptick in cosmetic procedures.

Closing out their discussion on the management of plaque psoriasis, panelists share their excitement for future directions in care.

Experts reflect on the treatment of patients with plaque psoriasis during the COVID-19 pandemic.

A brief discussion on the unmet needs and ongoing challenges in the treatment of plaque psoriasis.

Shared insight on which factors are most important in determining second-line therapy for plaque psoriasis.

Linda Stein Gold, MD, discusses psoriasis in 2022, in her presentation at the current Maui Derm for Dermatologists meeting.

New and exciting topical and oral therapies for psoriasis have changed the way dermatologists treat and manage their psoriasis patients.

Neal Bhatia, MD, highlights the most exciting new drugs and therapies in atopic dermatitis and psoriasis in his presentation at the current Maui Derm for Dermatologists meeting.

Moving on to the second patient case, panelists discuss switching therapy at treatment failure for plaque psoriasis.

Panelists share which factors they use to determine optimal therapy in the moderate to severe plaque psoriasis setting.

A research letter published by the Journal of the American Academy of Dermatology dove into the question of how psoriasis may increase the overall risk of cutaneous malignant melanoma in patients.

A study published in the Journal of the American Academy of Dermatology did a prospective analysis on psoriasis biologic treatment response related to comorbid obesity and a history of diabetes.

Dermavant had patient satisfaction data from the PSOARING 3 long term extension trial presented at the 2022 Winter Clinical Dermatology Conference.

One of the key differences between diagnosing AD in patients with skin of color compared to White skin is erythema.

Click here to answer this week's poll.

A panel of experts reflect on the toxicity profiles of biologic agents used to treat patients with plaque psoriasis.

A focused discussion on the benefit of bimekizumab, an IL-17A/IL-17F inhibitor, in the setting of moderate to severe plaque psoriasis.

Studies offer positive outcomes for patients with conditions like hidradenitis suppurativa or psoriasis.

A brief review of biologic agents being used or evaluated in the setting of plaque psoriasis.

Taking a broader look at moderate to severe plaque psoriasis, experts consider what the standard of care would be in different settings.